HK1255701A1 - 使用BCL-9的安定的α螺旋將癌症中失調WNT信號傳遞訂為目標 - Google Patents

使用BCL-9的安定的α螺旋將癌症中失調WNT信號傳遞訂為目標

Info

Publication number
HK1255701A1
HK1255701A1 HK18114851.9A HK18114851A HK1255701A1 HK 1255701 A1 HK1255701 A1 HK 1255701A1 HK 18114851 A HK18114851 A HK 18114851A HK 1255701 A1 HK1255701 A1 HK 1255701A1
Authority
HK
Hong Kong
Prior art keywords
helices
bcl
cancer
wnt signaling
stabilized alpha
Prior art date
Application number
HK18114851.9A
Other languages
English (en)
Inventor
L‧D‧瓦倫斯基
R‧卡拉斯科
G‧H‧伯德
Original Assignee
達納-法伯癌症研究所有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 達納-法伯癌症研究所有限公司 filed Critical 達納-法伯癌症研究所有限公司
Publication of HK1255701A1 publication Critical patent/HK1255701A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
HK18114851.9A 2011-04-15 2018-11-21 使用BCL-9的安定的α螺旋將癌症中失調WNT信號傳遞訂為目標 HK1255701A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161475932P 2011-04-15 2011-04-15

Publications (1)

Publication Number Publication Date
HK1255701A1 true HK1255701A1 (zh) 2019-08-23

Family

ID=47010037

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114851.9A HK1255701A1 (zh) 2011-04-15 2018-11-21 使用BCL-9的安定的α螺旋將癌症中失調WNT信號傳遞訂為目標

Country Status (9)

Country Link
US (3) US10703785B2 (zh)
EP (3) EP2697254B1 (zh)
JP (1) JP2014515748A (zh)
CN (2) CN103649113B (zh)
AU (1) AU2012242502B2 (zh)
CA (1) CA2833171C (zh)
ES (1) ES2815498T3 (zh)
HK (1) HK1255701A1 (zh)
WO (1) WO2012142604A2 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500817A (ja) 2009-08-04 2013-01-10 ポロゲン リミテッド 美容のための肌の活性化
EP2501352B1 (en) 2009-11-16 2016-07-13 Pollogen Ltd Device for non-invasive fat reduction comprising an applicator head with massage contacts and with electrodes
US11590346B2 (en) 2009-11-16 2023-02-28 Pollogen Ltd. Apparatus and method for cosmetic treatment of human mucosal tissue
EP2697254B1 (en) 2011-04-15 2018-06-06 Dana-Farber Cancer Institute, Inc. Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
FI125828B (en) 2013-11-18 2016-02-29 Teconer Oy rain sensor
CA2944043A1 (en) 2014-03-25 2015-10-01 University Of Utah Research Foundation Peptide inhibitors of bcr-abl oligomerization
MX2017016251A (es) * 2015-07-02 2018-04-20 Dana Farber Cancer Inst Inc Peptidos anti-microbianos estabilizados.
WO2017018595A1 (ko) * 2015-07-28 2017-02-02 동국대학교 산학협력단 이중 스테이플화된 펩타이드 및 이의 용도
WO2017062518A1 (en) * 2015-10-05 2017-04-13 Wntrx Pharmaceuticals Inc. Stabilized bcl9 peptides for treatment of aberrant wnt signaling
CN109069578A (zh) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
EP3214093A1 (en) * 2016-03-03 2017-09-06 Fondation The Ark Fusion respiratory syncytial virus inhibitors and use thereof
US11325955B2 (en) 2017-07-19 2022-05-10 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
KR20200064075A (ko) 2017-09-07 2020-06-05 포그 파마슈티컬스 인코포레이티드 베타-카테닌 기능을 조절하는 제제 및 이의 방법
US20210214724A1 (en) * 2017-10-23 2021-07-15 The Broad Institute, Inc. Novel nucleic acid modifiers
US11591365B2 (en) * 2017-11-09 2023-02-28 Wntrx Pharmaceuticals Inc. BCL9 peptides and variants thereof
WO2020037119A1 (en) * 2018-08-16 2020-02-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stapled peptides as pyrin-domain targeted nlrp3 inflammasome inhibitors
US11884749B2 (en) 2018-11-21 2024-01-30 Endomet Biosciences, Inc. Compositions and methods for treating endometriosis
CN110003312A (zh) * 2019-03-05 2019-07-12 复旦大学 一种抗肿瘤的多肽及其应用
CN109750055B (zh) * 2019-03-13 2022-12-23 南开大学 基于α螺旋把手提高蛋白核酸生物耦合效率的方法
MX2022000283A (es) * 2019-07-05 2022-09-23 Sapience Therapeutics Inc Peptidos mimetidos de bcl9 modificados.
CN111909242B (zh) * 2020-07-28 2021-12-17 西安交通大学医学院第一附属医院 高亲和力特异性结合β-catenin蛋白的多肽及其应用和合成方法
CN111718406B (zh) * 2020-07-31 2022-12-06 西安交通大学医学院第一附属医院 一种纳米多肽载体及其制备方法和应用
WO2023159052A2 (en) * 2022-02-15 2023-08-24 Transira Therapeutics, Llc Stapled peptides, methods of making same, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US7049290B2 (en) * 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2332968B1 (en) * 2003-11-05 2016-05-04 Dana-Farber Cancer Institute, Inc. Alpha-helical peptides suitable for activating or inhibiting cell death
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
WO2009108261A2 (en) 2008-01-23 2009-09-03 Dana Farber Cancer Institute Compositions and methods for the treatment of viral infections
CA2761568C (en) 2009-06-18 2020-10-13 Dana-Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
US9163330B2 (en) * 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2697254B1 (en) 2011-04-15 2018-06-06 Dana-Farber Cancer Institute, Inc. Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9

Also Published As

Publication number Publication date
US10703785B2 (en) 2020-07-07
ES2815498T3 (es) 2021-03-30
EP3715366A1 (en) 2020-09-30
EP3360892A1 (en) 2018-08-15
EP3360892B1 (en) 2020-06-10
US20140113857A1 (en) 2014-04-24
EP2697254B1 (en) 2018-06-06
EP2697254A4 (en) 2014-12-17
US20210002336A1 (en) 2021-01-07
CA2833171C (en) 2021-08-31
CN108276490B (zh) 2022-07-05
CN103649113A (zh) 2014-03-19
AU2012242502A1 (en) 2013-10-24
EP2697254A2 (en) 2014-02-19
AU2012242502B2 (en) 2016-07-28
CN103649113B (zh) 2018-01-12
US20220204572A1 (en) 2022-06-30
WO2012142604A3 (en) 2012-12-27
CA2833171A1 (en) 2012-10-18
JP2014515748A (ja) 2014-07-03
CN108276490A (zh) 2018-07-13
US11220532B2 (en) 2022-01-11
WO2012142604A2 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
HK1255701A1 (zh) 使用BCL-9的安定的α螺旋將癌症中失調WNT信號傳遞訂為目標
HK1197182A1 (zh) 癌症免疫療法
EP2749642A4 (en) INDUCED MALIGNANT STEM CELLS
ZA201402794B (en) Porous proppants
EP2772268A4 (en) CRAB STEM CELL SPECIFIC MOLECULE
SI2547205T1 (sl) Novi postopki za ciljanje rakastih matičnih celic
GB201016139D0 (en) Cancer phosholipidome
ZA201209029B (en) Novel pyrimidine derivatives
HUE066482T2 (hu) Új eljárások rákõssejtek megcélzására
PL2771659T3 (pl) Termoelement
GB201120860D0 (en) Cancer immunotherapy
EP2618053A4 (en) COMBUSTION HEATER
GB201114098D0 (en) Armoured over-trousers
EP2738463A4 (en) COMBUSTION HEATER
IL233001A0 (en) New iso-ergoline histories
EP2783159A4 (en) COMBUSTION CHAMBER
EP2738462A4 (en) COMBUSTION HEATER
EP2681337A4 (en) VARIANTS AT RISK FOR CANCER
PT2546846T (pt) Fecho para manga
EP2732287A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2695868A4 (en) REFRACTORY
IL229109A0 (en) Cancer diagnosis
IL228629A0 (en) Cancer detection
GB2488834B (en) Snow shovel-scoop
GB201118825D0 (en) Reelsafe wallet